siRNA AAV Vectors for HTT Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Huntington's Disease primarily offer symptomatic relief and do not address the underlying cause, as they fail to effectively inhibit the expression of the mutated Huntingtin protein responsible for neurodegeneration.
Innovation Solution
The use of small interfering RNA (siRNA) molecules, specifically designed to target and inhibit the Huntingtin (HTT) gene expression, delivered via adeno-associated viral vectors, to reduce the production of toxic HTT protein in neurons and astrocytes, thereby ameliorating disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If symptomatic relief therapies are used for Huntington's Disease, then disease symptoms are temporarily alleviated, but the underlying cause (mutated HTT protein production) remains untreated
Solution Approach 1:
The patent extracts and targets the specific genetic cause of Huntington's Disease by using siRNA molecules designed to bind to and silence the mutated HTT gene transcript, thereby removing the root cause rather than merely treating symptoms. This is achieved through sequence-specific RNA interference that selectively targets the expanded CAG repeat region in the HTT gene.
Solution Approach 2:
The patent employs adeno-associated viral vectors as intermediary carriers to deliver the therapeutic siRNA molecules into the central nervous system. The viral vector acts as a mediator that protects the siRNA from degradation and facilitates its transport across the blood-brain barrier to reach target neurons in the striatum and cortex.
2Reliability
If siRNA molecules are delivered via adeno-associated viral vectors, then HTT gene expression is significantly inhibited, but delivery complexity and manufacturing challenges increase
Solution Approach 1:
The patent incorporates the siRNA encoding sequence directly into the viral vector genome during manufacturing, preparing the complete therapeutic construct in advance. This preliminary action ensures that the siRNA is pre-assembled with its delivery vehicle, eliminating the need for complex in vivo assembly steps and improving manufacturing reliability.
Solution Approach 2:
The adeno-associated viral vector serves multiple functions simultaneously: it acts as a protective carrier for the siRNA, provides targeted delivery to the central nervous system, enables sustained expression of the therapeutic agent, and facilitates crossing of the blood-brain barrier. This multi-functionality reduces the need for additional separate delivery components.
3Ease of operation
If current symptomatic treatments are used, then treatment simplicity is maintained, but therapeutic effectiveness against the disease cause is insufficient
Solution Approach 1:
The siRNA molecules are designed to self-assemble into RNA-induced silencing complexes (RISC) after delivery, automatically targeting and degrading their complementary HTT gene transcript without requiring additional cellular machinery or complex processing steps. This self-service capability simplifies the therapeutic mechanism while maintaining high effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly inhibits HTT gene expression, leading to reduced neurotoxicity and potential therapeutic benefits by silencing the mutated HTT gene, offering a promising treatment for Huntington's Disease.
Implementation Method 1
The nucleic acid sequence may be inserted into an adeno-associated viral vector and introduced into cells
Implementation Method 2
small interfering RNA (siRNA) molecules, specifically designed to target and inhibit the Huntingtin (HTT) gene expression
Implementation Method 3
a dsRNA having an antisense strand that is substantially complementary to at least part of an mRNA transcript of the mutated HTT gene
Data Source
AI summary
The present invention relates to small interfering RNA (siRNA) molecules against the HTT gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating Huntington's Disease (HD) using the siRNA molecules and AAV vectors.